Haleon (HLN) Net Income towards Common Stockholders (2021 - 2023)

Haleon (HLN) posted Net Income towards Common Stockholders of $852.7 million for Q4 2023, up 128.66% on a QoQ basis from $372.9 million in Q2 2023, and down 15.67% year-over-year from $1.0 billion in Q4 2022.

Haleon (HLN) Net Income towards Common Stockholders (2021 - 2023) Analysis & Trends

Haleon's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at $852.7 million for Q4 2023.

  • Quarterly Net Income towards Common Stockholders fell 15.67% year-over-year to $852.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $852.7 million (down 30.43% YoY) and the FY2025 annual result came in at $2.2 billion, up 19.24% from the prior year.
  • Net Income towards Common Stockholders was $852.7 million for Q4 2023 at Haleon, up from $372.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.2 billion in Q4 2021 and bottomed at $372.9 million in Q2 2023.
  • A 3-year average of $751.8 million and a median of $744.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slipped 12.99% — and 2023, when it retreated 15.67%.
  • Haleon's Net Income towards Common Stockholders stood at $1.2 billion in 2021, then slipped by 12.99% to $1.0 billion in 2022, then declined by 15.67% to $852.7 million in 2023.
  • Business Quant data shows HLN's Net Income towards Common Stockholders at $852.7 million in Q4 2023, $372.9 million in Q2 2023, and $475.7 million in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn -22.50 Mn

Historic Data

Download Data
DateValue
Dec 31, 2023 852.67 Mn
Jun 30, 2023 372.91 Mn
May 3, 2023 475.66 Mn
Dec 31, 2022 1.01 Bn
Sep 20, 2022 636.58 Mn
Dec 31, 2021 1.16 Bn